Home / Market News / $ARGX
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

UBS Raises Price Target for argenx

Oct 26, 2026, 1:03 PM UTC · Primary ticker $ARGX

UBS has increased its price target for argenx to $1350 from $1300, maintaining a 'Buy' rating, following the company's strong quarterly financial results. This adjustment signals continued analyst confidence in the biopharmaceutical company's performance and future prospects.

UBS analyst Xian Deng raised the price target for argenx to $1350 from $1300, while reiterating a 'Buy' rating. This positive adjustment stems from the company's recent strong quarterly financial results, indicating robust operational performance. For traders, this signals continued analyst confidence and could lead to short-term positive momentum for ARGENX stock. Long-term, it reinforces the bullish outlook on the biopharmaceutical company, although future performance will depend on continued strong results and pipeline developments. A key opportunity for traders is to capitalize on potential upward price movement driven by this analyst upgrade.

$ARGX positive Price target increase and maintained 'Buy' rating
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.